Cargando…

Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients

To evaluate the clinical relevance of urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-1) measured by a recently developed enzyme-linked immunosorbent assay (ELISA), we analysed both components in samples derived from 892 patients with primary breast cancer (median follow-up...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Witte, J H, Sweep, C G J, Klijn, J G M, Grebenschikov, N, Peters, H A, Look, M P, van Tienoven, Th H, Heuvel, J J T M, van Putten, W L J, Benraad, Th J, Foekens, J A
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1999
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362263/ https://www.ncbi.nlm.nih.gov/pubmed/10098758 http://dx.doi.org/10.1038/sj.bjc.6690191

Ejemplares similares

Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumours
por: Witte, J H de, et al.
Publicado: (2001)

Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer
por: Witte, J H de, et al.
Publicado: (1999)

External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts.
por: Sweep, C. G., et al.
Publicado: (1998)

Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas.
por: Bouchet, C., et al.
Publicado: (1994)

Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) in breast cancer - correlation with traditional prognostic factors
por: Lampelj, Maja, et al.
Publicado: (2015)

The autoactivation of human single-chain urokinase-type plasminogen activator (uPA)
por: Torres-Paris, Constanza, et al.
Publicado: (2023)

Urokinase-type plasminogen activator (uPA) regulates invasion and matrix remodelling in colorectal cancer
por: Micalet, Auxtine, et al.
Publicado: (2023)

A Key Role for the Urokinase Plasminogen Activator (uPA) in Invasive Group A Streptococcal Infection
por: Sanderson-Smith, Martina L., et al.
Publicado: (2013)

Microglia and the urokinase plasminogen activator receptor/uPA system in innate brain inflammation
por: Cunningham, Orla, et al.
Publicado: (2009)

Correlation of Serum Levels of Urokinase Activation Plasminogen (uPA) and Its Inhibitor (PAI-1) with Hormonal and HER-2 Status in the Early Invasive Breast Cancer
por: Pusina, Sadat
Publicado: (2018)

Multifunctional roles of urokinase plasminogen activator (uPA) in cancer stemness and chemoresistance of pancreatic cancer
por: Asuthkar, Swapna, et al.
Publicado: (2013)

Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc
por: Kuhn, W, et al.
Publicado: (1999)

Increased expression of urokinase type plasminogen activator(u-PA), plasminogen activator inhibitor-1(PAI-1), and collagenases in Caco-2 cells infected by Salmonella typhimurium.
por: Park, C. G., et al.
Publicado: (1997)

The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer
por: Banys-Paluchowski, Malgorzata, et al.
Publicado: (2019)

uPA-mediated plasminogen activation is enhanced by polyphosphate
por: Whyte, Claire S., et al.
Publicado: (2020)

Inhibition of Human Urokinase-Type Plasminogen Activator (uPA) Enzyme Activity and Receptor Binding by DNA Aptamers as Potential Therapeutics through Binding to the Different Forms of uPA
por: Dreymann, Nico, et al.
Publicado: (2022)

Inhibition of urokinase plasminogen activator “uPA” activity alters ethanol consumption and conditioned place preference in mice
por: Al Maamari, Elyazia, et al.
Publicado: (2014)

Urokinase-type plasminogen activator (uPA) and its receptor (uPAR) promote neurorepair in the ischemic brain
por: Merino, Paola, et al.
Publicado: (2017)

Time-varying prognostic impact of tumour biological factors urokinase (uPA), PAI-1 and steroid hormone receptor status in primary breast cancer.
por: Schmitt, M., et al.
Publicado: (1997)

Urokinase-type Plasminogen Activator (uPA) is Inhibited with QLT0267 a Small Molecule Targeting Integrin-linked Kinase (ILK)
por: Santos, Nancy Dos, et al.
Publicado: (2007)

Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications
por: Mahmood, Niaz, et al.
Publicado: (2018)

Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer.
por: Foekens, J. A., et al.
Publicado: (1994)

Comparison of immunohistochemistry with immunoassay (ELISA) for the detection of components of the plasminogen activation system in human tumour tissue
por: Ferrier, C M, et al.
Publicado: (1999)

A Pilot Study of Urokinase-Type Plasminogen Activator (uPA) Overexpression in the Brush Cytology of Patients with Malignant Pancreatic or Biliary Strictures
por: Gibbs, John F., et al.
Publicado: (2009)

Prognostic value of cytosolic tyrosine kinase activity in 249 node-positive breast cancer patients.
por: Romain, S., et al.
Publicado: (1994)

Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer.
por: Knoop, A., et al.
Publicado: (1998)

Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients
por: Foekens, J A, et al.
Publicado: (1999)

Genetics of Plasminogen Activator Inhibitor-1 (PAI-1) in a Ghanaian Population
por: White, Marquitta J., et al.
Publicado: (2015)

Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma.
por: Cantero, D., et al.
Publicado: (1997)

Soluble urokinase plasminogen activator receptor predicts mortality in exacerbated COPD
por: Godtfredsen, Nina S., et al.
Publicado: (2018)

Expression of uPA, tPA, and PAI-1 in Calcified Aortic Valves
por: Kochtebane, Najlah, et al.
Publicado: (2014)

Combined mRNA expression levels of members of the urokinase plasminogen activator (uPA) system correlate with disease-associated survival of soft-tissue sarcoma patients
por: Kotzsch, Matthias, et al.
Publicado: (2011)

uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies
por: Duffy, Michael J, et al.
Publicado: (2014)

Soluble urokinase plasminogen activator receptor for the prediction of ventilator-associated pneumonia
por: van Oort, Pouline M., et al.
Publicado: (2019)

Plasminogen Activator Inhibitor-1 Protects Mice Against Cardiac Fibrosis by Inhibiting Urokinase-type Plasminogen Activator-mediated Plasminogen Activation
por: Gupta, Kamlesh K., et al.
Publicado: (2017)

The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy
por: Manders, P, et al.
Publicado: (2002)

Molecular imaging of the urokinase plasminogen activator receptor: opportunities beyond cancer
por: Baart, V. M., et al.
Publicado: (2020)

Uncharged isocoumarin-based inhibitors of urokinase-type plasminogen activator
por: Heynekamp, Justin J, et al.
Publicado: (2006)

Impact of uPA/PAI-1 and disseminated cytokeratin-positive cells in breast cancer
por: Märkl, Bruno, et al.
Publicado: (2019)

Urokinase Plasminogen Activator Receptor (uPAR) and Plasminogen Activator Inhibitor-1 (PAI-1) Are Potential Predictive Biomarkers in Early Stage Oral Squamous Cell Carcinomas (OSCC)
por: Magnussen, Synnøve, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_6g2njrtau49cf38t5e7qeh0u23